A publication on cardiovascular biomakers from the group of Prof. Peter van der Meer, Cardiology Dept, UMCG.
Heart failure (HF) is a common manifestation of patients with primary and secondary causes of iron overload, whereas in patients with established HF iron deficiency impairs outcome. Whether iron stores, either depleted or in overload, amplify the risk for new-onset HF among healthy individuals is unknown.
In this paper, Klipt et al. aimed to assess whether markers of iron status or the iron-regulatory hormone hepcidin are associated with new-onset HF or cardiovascular (CV) events. The investigation was conducted in 6386 subjects from the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) trial, a prospective, community-based, cohort study. Results of the study showed that increased serum ferritin levels independently amplify the risk for new-onset HF in women in the community.
You can find the assays for cardiovascular biomarkers as serum iron, ferritin and transferrin available on the BiomarkerBay database.